secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001641172-25-003501
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics appoints Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor
--------------------------------------------------------------------------------

- Appointment effective April 8, 2025; one-year term with monthly consulting fee of $20,833.33.
- Dr. Clifton is a practicing surgical oncologist with 17+ years experience, previously CMO at Parthenon Therapeutics.
- Appointment coincides with recently filed IND for CLD-201 dose escalation trial in solid tumors.
- Dr. Clifton has over 80 peer-reviewed publications and served as U.S. Army Colonel with four Afghanistan deployments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225003501/0001641172-25-003501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225003501/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-003501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer